Early Access — free while we kick the tires
EdgarHawk

SNES SenesTech, Inc. Insider Trading

Latest: Insider Bought $4,407 of Shares · Apr 2026
2 filings analyzed · Latest 2026-05-18
Insider buys
2
Insider sells
0
Unique insiders
1
Direction
Net buying
May 2026
2026-05-18
medium
Capital Management Glenbrook Buy
32,120 shares
$53,486
@ $1.67
Significance 3/10

Capital Management Glenbrook (10% owner) purchases 32,120 shares at blended avg $1.67; stock -74.5% from 52-wk high, -32.6% over 90 days.

Capital Management Glenbrook executed 3 separate purchases totaling 32,120 shares for $53,486.08 between May 14–18, 2026, increasing holdings by 3.6% to 925,755 shares at prices ranging from $1.59 to $1.72. The timing occurs amid significant price pressure: the stock is down -32.6% over the past 90 days and -74.5% from its 52-week high of $6.24, while the company reports quarterly revenue of $493,000.00 and is unprofitable ($-2,063,000.00 net loss). Reviewing the insider's prior 5 trades at SNES, only 1 of 5 buys produced a positive 90-day return, and the most recent purchase on 2026-04-28 (+10.3% at 90 days) is the sole instance of well-timed entry at this ticker. The broader cross-ticker track record shows median underperformance (90-day win rate 14.29%), suggesting the insider's prior buy decisions have struggled to anticipate positive price movements. The severity of the stock's recent decline and the weak historical accuracy of this insider's timing at SNES warrant investor scrutiny of the company's operational and financial trajectory.

April 2026
2026-04-30
low
GLENBROOK CAPITAL MANAGEMENT Buy
3,000 shares
$4,407
@ $1.47
Significance 4/10

10% owner Glenbrook Capital purchases 3,000 shares of struggling biotech as stock hits 52-week lows.

Glenbrook Capital Management, a significant institutional holder with over 10% ownership, purchased 3,000 shares near the stock's recent bottom, suggesting deliberate portfolio averaging rather than strategic conviction. The company is pre-revenue in practical terms—annual revenue trails operating losses by more than tenfold—and the stock trades substantially below its highs from earlier in the year. While Glenbrook's purchase at depressed valuation could signal a belief that SenesTech's biotech prospects are underpriced, institutional purchases at distressed prices are routine portfolio management moves and do not carry the weight of insider conviction from executives with operational knowledge. The small transaction size relative to Glenbrook's existing position further suggests tactical rebalancing rather than a bold bullish statement.

More Chemicals and Allied Products companies

Get alerts for SNES

Add SNES to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access